Innovation Platform Licensing


Licensing an exclusive agreement

Vivasolis has been executed an exclusive license agreement with academic to develop the brand new human derived antibody as a targeted immunotherapy for chronic disease.

Under the agreement, Vivasolis has acquired the exclusive rights to all intellectual property, including relevant patents, related to M Factor antibodies as the chronic disease therapy.

Vivasolis is based on the innovative science developed by the professional team with both academic and industry experience.